ALLOGENE THERAPEUTICS INC's ticker is ALLO and the CUSIP is 019770106. A total of 179 filers reported holding ALLOGENE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.67 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $6,240 | -47.9% | 2,678 | 0.0% | 0.00% | – |
| Q1 2024 | $11,971 | +39.3% | 2,678 | 0.0% | 0.00% | – |
| Q4 2023 | $8,596 | -5.6% | 2,678 | -6.8% | 0.00% | – |
| Q3 2023 | $9,104 | -26.7% | 2,872 | +14.9% | 0.00% | – |
| Q2 2023 | $12,425 | -0.6% | 2,500 | -1.2% | 0.00% | – |
| Q1 2023 | $12,503 | -21.5% | 2,531 | 0.0% | 0.00% | – |
| Q4 2022 | $15,920 | -41.0% | 2,531 | 0.0% | 0.00% | – |
| Q3 2022 | $27,000 | -6.9% | 2,531 | 0.0% | 0.00% | – |
| Q2 2022 | $29,000 | +7.4% | 2,531 | -15.1% | 0.00% | – |
| Q1 2022 | $27,000 | -38.6% | 2,981 | +0.6% | 0.00% | – |
| Q4 2021 | $44,000 | -42.1% | 2,964 | +0.5% | 0.00% | – |
| Q3 2021 | $76,000 | -1.3% | 2,950 | -0.6% | 0.00% | – |
| Q2 2021 | $77,000 | -26.0% | 2,969 | +0.6% | 0.00% | – |
| Q1 2021 | $104,000 | +40.5% | 2,950 | 0.0% | 0.00% | – |
| Q4 2020 | $74,000 | -33.3% | 2,950 | 0.0% | 0.00% | – |
| Q3 2020 | $111,000 | +3.7% | 2,950 | +18.0% | 0.00% | – |
| Q2 2020 | $107,000 | – | 2,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vida Ventures Advisors, LLC | 1,798,163 | $26,829,000 | 10.04% |
| Wildcat Capital Management, LLC | 1,716,370 | $25,608,000 | 4.17% |
| TPG GP A, LLC | 18,716,306 | $279,247,000 | 2.79% |
| Casdin Capital, LLC | 2,650,000 | $39,538,000 | 1.11% |
| Lombard Odier Asset Management (Switzerland) SA | 996,116 | $14,862,000 | 0.95% |
| Coastal Bridge Advisors, LLC | 301,929 | $4,505,000 | 0.94% |
| HARBOR CAPITAL ADVISORS, INC. | 119,547 | $1,784,000 | 0.65% |
| Pier Capital, LLC | 294,968 | $4,401,000 | 0.46% |
| Navalign, LLC | 64,428 | $961,000 | 0.38% |
| Gratus Capital, LLC | 191,871 | $2,863,000 | 0.26% |